Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Chronic anthracycline cardiotoxicity: molecular and functional analysis with focus on nuclear factor erythroid 2-related factor 2 and mitochondrial biogenesis pathways

E. Jirkovsky, O. Popelová, P. Kriváková-Stanková, A. Vávrová, M. Hroch, P. Hasková, E. Brcáková-Dolezelová, S. Micuda, M. Adamcová, T. Simůnek, Z. Cervinková, V. Gersl, M. Sterba

. 2012 ; 343 (2) : 468-78.

Jazyk angličtina Země Spojené státy americké

Typ dokumentu časopisecké články, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc13012518

Anthracycline anticancer drugs (e.g., doxorubicin or daunorubicin) can induce chronic cardiotoxicity and heart failure (HF), both of which are believed to be based on oxidative injury and mitochondrial damage. In this study, molecular and functional changes induced by chronic anthracycline treatment with progression into HF in post-treatment follow-up were analyzed with special emphasis on nuclear factor erythroid 2-related factor 2 (Nrf2) and peroxisome proliferator-activated receptor-γ coactivator-1α (PGC1α) pathways. Chronic cardiotoxicity was induced in rabbits with daunorubicin (3 mg/kg, weekly for 10 weeks), and the animals were followed for another 10 weeks. Echocardiography revealed a significant drop in left ventricular (LV) systolic function during the treatment with marked progression to LV dilation and congestive HF in the follow-up. Although daunorubicin-induced LV lipoperoxidation was found, it was only loosely associated with cardiac performance. Furthermore, although LV oxidized glutathione content was increased, the oxidized-to-reduced glutathione ratio itself remained unchanged. Neither Nrf2, the master regulator of antioxidant response, nor the majority of its target genes showed up-regulation in the study. However, down-regulation of manganese superoxide dismutase and NAD(P)H dehydrogenase [quinone] 1 were observed together with heme oxygenase 1 up-regulation. Although marked perturbations in mitochondrial functions were found, no induction of PGC1α-controlled mitochondrial biogenesis pathway was revealed. Instead, especially in the post-treatment period, an impaired regulation of this pathway was observed along with down-regulation of the expression of mitochondrial genes. These results imply that global oxidative stress need not be a factor responsible for the development of anthracycline-induced HF, whereas suppression of mitochondrial biogenesis might be involved.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc13012518
003      
CZ-PrNML
005      
20130526185007.0
007      
ta
008      
130404s2012 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1124/jpet.112.198358 $2 doi
035    __
$a (PubMed)22915767
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Jirkovský, Eduard. $7 uk20201094982 $u Department of Pharmacology, Faculty of Medicine in Hradec Králové, Charles University in Prague, Šimkova 870, Hradec Králové, 500 38, Czech Republic.
245    10
$a Chronic anthracycline cardiotoxicity: molecular and functional analysis with focus on nuclear factor erythroid 2-related factor 2 and mitochondrial biogenesis pathways / $c E. Jirkovsky, O. Popelová, P. Kriváková-Stanková, A. Vávrová, M. Hroch, P. Hasková, E. Brcáková-Dolezelová, S. Micuda, M. Adamcová, T. Simůnek, Z. Cervinková, V. Gersl, M. Sterba
520    9_
$a Anthracycline anticancer drugs (e.g., doxorubicin or daunorubicin) can induce chronic cardiotoxicity and heart failure (HF), both of which are believed to be based on oxidative injury and mitochondrial damage. In this study, molecular and functional changes induced by chronic anthracycline treatment with progression into HF in post-treatment follow-up were analyzed with special emphasis on nuclear factor erythroid 2-related factor 2 (Nrf2) and peroxisome proliferator-activated receptor-γ coactivator-1α (PGC1α) pathways. Chronic cardiotoxicity was induced in rabbits with daunorubicin (3 mg/kg, weekly for 10 weeks), and the animals were followed for another 10 weeks. Echocardiography revealed a significant drop in left ventricular (LV) systolic function during the treatment with marked progression to LV dilation and congestive HF in the follow-up. Although daunorubicin-induced LV lipoperoxidation was found, it was only loosely associated with cardiac performance. Furthermore, although LV oxidized glutathione content was increased, the oxidized-to-reduced glutathione ratio itself remained unchanged. Neither Nrf2, the master regulator of antioxidant response, nor the majority of its target genes showed up-regulation in the study. However, down-regulation of manganese superoxide dismutase and NAD(P)H dehydrogenase [quinone] 1 were observed together with heme oxygenase 1 up-regulation. Although marked perturbations in mitochondrial functions were found, no induction of PGC1α-controlled mitochondrial biogenesis pathway was revealed. Instead, especially in the post-treatment period, an impaired regulation of this pathway was observed along with down-regulation of the expression of mitochondrial genes. These results imply that global oxidative stress need not be a factor responsible for the development of anthracycline-induced HF, whereas suppression of mitochondrial biogenesis might be involved.
650    _2
$a zvířata $7 D000818
650    _2
$a antracykliny $x toxicita $7 D018943
650    _2
$a protinádorová antibiotika $x toxicita $7 D000903
650    _2
$a buněčné jádro $x účinky léků $x metabolismus $7 D002467
650    _2
$a daunomycin $x farmakologie $7 D003630
650    _2
$a echokardiografie $7 D004452
650    _2
$a glutathion $x metabolismus $7 D005978
650    _2
$a nemoci srdce $x chemicky indukované $x metabolismus $7 D006331
650    _2
$a funkční vyšetření srdce $7 D006334
650    _2
$a srdeční komory $x účinky léků $x metabolismus $7 D006352
650    _2
$a peroxidace lipidů $x účinky léků $7 D015227
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a srdeční mitochondrie $x účinky léků $x metabolismus $7 D008929
650    _2
$a myokard $x patologie $7 D009206
650    _2
$a faktor 2 související s NF-E2 $x biosyntéza $7 D051267
650    _2
$a oxidační stres $x účinky léků $7 D018384
650    _2
$a králíci $7 D011817
650    _2
$a kvantitativní polymerázová řetězová reakce $7 D060888
650    _2
$a přežití $7 D013534
650    _2
$a transkripční faktory $x metabolismus $7 D014157
650    _2
$a troponin T $x metabolismus $7 D020107
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1#
$a Popelová, Olga. $7 _BN001885
700    1_
$a Křiváková, Pavla, $d 1979- $7 stk2008428620
700    1#
$a Vávrová, Anna. $7 _AN050099
700    1_
$a Hroch, Miloš, $d 1976- $7 xx0076212
700    1#
$a Hašková, Pavlína. $7 xx0267424
700    1#
$a Doleželová, Eva. $7 xx0179807
700    1_
$a Mičuda, Stanislav, $d 1972- $7 jn20010309083
700    1_
$a Adamcová, Michaela, $d 1964- $7 xx0064762
700    1_
$a Šimůnek, Tomáš $7 xx0019029
700    1_
$a Červinková, Zuzana, $d 1951- $7 nlk20020106444
700    1_
$a Geršl, Vladimír, $d 1946-2015 $7 nlk19990073168
700    1_
$a Sterba, Martin $u -
773    0_
$w MED00002900 $t The Journal of pharmacology and experimental therapeutics $x 1521-0103 $g Roč. 343, č. 2 (2012), s. 468-78
856    41
$u https://pubmed.ncbi.nlm.nih.gov/22915767 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20130404 $b ABA008
991    __
$a 20130526185358 $b ABA008
999    __
$a ok $b bmc $g 975716 $s 810799
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2012 $b 343 $c 2 $d 468-78 $i 1521-0103 $m The Journal of pharmacology and experimental therapeutics $n J Pharmacol Exp Ther $x MED00002900
LZP    __
$a Pubmed-20130404

Najít záznam

Citační ukazatele

Nahrávání dat ...

Možnosti archivace

Nahrávání dat ...